This Study is to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of HSK47388 in Healthy Volunteers

Phase 1 Not yet recruiting 40 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and PK of HSK47388 in healthy adult participants and preliminarily evaluate the PD of HSK47388

Timeline

Start: 2025-05
Primary completion: 2025-07
Completion: 2025-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK47388	Unknown	—	Oral

Indications

No indication recorded.